2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE OF SAID COMPOUND Russian patent published in 2019 - IPC C07D239/48 C07D401/12 C07D403/12 A61K31/505 A61K31/506 A61K31/535 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to organic chemistry and specifically to novel compounds of 2-aminopyrimidine of formula I, where R₁ is selected from a group comprising halogen, cyano, substituted or unsubstituted C₁-C₆ alkyl or unsubstituted C₁-C₆ alkoxy; R₂ is selected from a group comprising H, halogen, unsubstituted C₁-C₆ alkyl, unsubstituted C₁-C₆ alkoxy; R₃ is H or -(CH₂)_mNR₈R₉; R₄ and R₅ each being H, unsubstituted C₁-C₆ alkyl, halogen, -(CH₂)_mNR₈R₉; wherein each m separately represents 0 or 1; each R₈ and each R₉ separately is selected from substituted and unsubstituted C₁-C₆ alkyl, or R₈, R₉ and bound N together form an unsubstituted or substituted 4–7 membered monocyclic ring containing 1 or 2 heteroatoms selected from O, N; W is NH, N(C₁-C₃ alkyl), O or S; X, Y, Z each separately is N or -CR₁₀, where R₁₀ is H; is unsubstituted 5-6-member aromatic ring containing 0, 1 heteroatoms selected from N; where each substituted element is separately substituted with 1 or 3 groups selected from halogen, C₁-C₃ alkyl, -NH(C₁-C₃ alkyl), -N(C₁-C₃ alkyl)(C₁-C₃ alkyl) and - C(= O)(C₁-C₃ alkyl). Also disclosed is a method of producing said compound, a pharmaceutical composition based on said compound, use of said compound for treating a tumour for preparing a medicament of a protease inhibitor EGFR or for preparing a medicinal agent of a protease inhibitor IGF1R. Also disclosed is an intermediate compound of formula III.

,

EFFECT: technical result is obtaining heterocyclic compounds useful as EGFR protease inhibitor or IGF1R protease inhibitor.

13 cl, 3 dwg, 2 tbl, 53 ex